Eric Lefkofsky’s Post

A great way to improve access to trials- especially in Oncology where “Time is Life”. Key excerpt below: Tempus AI launched TIME in 2019 in an effort to bring clinical trials to patients in communities across the U.S., building a standardized operational framework and a just-in-time network that brings trials to patients in an average of approximately 10 days. Since then, TIME has seamlessly connected patients, their providers, and trial sponsors to enroll and activate trials for patients closer to home in a fraction of the time it has historically taken. Tempus has already enabled over one thousand patients in the community to be consented into TIME trials. Tempus and OneOncology aim to accelerate that momentum to ensure that the right patients are matched to the right trial at the right time. #clinicaldevelopment #oncology

Oncology clinical trials are uniquely complex. Maximizing your #eCOA can help. Download our newest infographic to stay up-to-date on the latest eCOA oncology clinical trial insights here: https://hubs.ly/Q02qx-dQ0

Valuable information #oncology #clinicaltrial professionals.

Adopting flexible and adaptive trial designs in early phase oncology studies can result in safer, more informed decision-making – lowering risk and improving subject safety. In this insight brief, we explore the specific challenges that sponsors need to be aware of when executing early phase oncology trials. Download now. https://bit.ly/3xGbxhm #oncology #clinicaltrials #earlyphaseoncology

Missed the live webinar on the Strategic Implications of Oncology Clinical Trial Design in Early-Phase Studies? Don't worry! You can now watch the on-demand recording at your convenience. Gain valuable insights into optimizing clinical trial design and stay up-to-date with the latest trends in oncology research. Click the link below to access the recording. #webinarrecording #oncologyresearch #clinicaltrialdesign https://lnkd.in/gYgMAndn

Phase 1 clinical trials in oncology are essential to the natural progression of any clinical compound or device, but remain some of the most unique and challenging trials that a research site can embark on. This document outlines several of the major considerations that a site should explore when considering Phase 1 oncology trials. Many of these aspects are also applicable to other therapeutic areas, but most pertain to oncology trials. Access it here ⇢ https://lnkd.in/gBqrX2TX

Thinking about adding Phase 1 trials to your portfolio? Phase 1 studies are the foundation of advancing medical breakthroughs for patients. Success starts with careful planning and the right team. The SCRS guide highlights key considerations for running these critical trials, including insights into operations and staffing. At UpTrials, we specialize in connecting research teams with the talent needed to support innovative treatments and improve patient outcomes.

Are you navigating the complex world of oncology clinical pathways? Our latest white paper reveals key insights on communicating value to pathway developers. Download now to optimize your engagement strategy! https://lnkd.in/eJ5ajU56 #oncologypathways #marketaccess #oncology

Phase 1 oncology research is essential to any clinical compound or device. Yet these can be some of the most unique and challenging trials to undertake. Understand the major considerations for Phase 1 oncology trials to prepare your site for success ⇢ https://lnkd.in/eStKf9-9